Editorial Material
Medicine, General & Internal
John M. M. Carethers
Summary: A 56-year-old man with no significant medical history declined screening colonoscopy in the past but now wants a less invasive test due to his father's death from colorectal cancer. What is the next course of action?
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Gastroenterology & Hepatology
Sanya Anand, Peter S. Liang
Summary: The multitarget stool DNA test (sDNA-FIT) is recommended as an option for colorectal cancer screening, with high sensitivity but low specificity. It includes a patient navigation system for education and reminders. The cost is covered by insurance.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
(2022)
Article
Medicine, General & Internal
Erica K. Barnell, Elizabeth M. Wurtzler, Julie La Rocca, Thomas Fitzgerald, Jessica Petrone, Yansheng Hao, Yiming Kang, Faith L. Holmes, David A. Lieberman
Summary: This study evaluated the sensitivity and specificity of a noninvasive multitarget stool RNA test for colorectal cancer and precancerous lesions. The results showed that the test had a sensitivity of 94% for detecting colorectal cancer and 46% for detecting advanced adenomas, with a specificity of 88%.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Oncology
Anton Gies, Tobias Niedermaier, Laura Fiona Gruner, Thomas Heisser, Petra Schrotz-King, Hermann Brenner
Summary: FOBTs show lower sensitivities in detecting early-stage colorectal cancer, particularly T1 cancers. Further research should focus on improving the detection of early-stage cancer.
Review
Health Policy & Services
Siddhartha Roy, Sabrina Dickey, Hsiao-Lan Wang, Alexandria Washington, Randy Polo, Clement K. Gwede, John S. Luque
Summary: African Americans experience disparities in colorectal cancer screening compared to other racial groups in the United States. Interventions such as mailed reminders, patient navigation, and tailored educational materials show promise in increasing participation rates in stool blood testing. More research is needed to determine the effectiveness of interventions in this population.
JOURNAL OF COMMUNITY HEALTH
(2021)
Letter
Gastroenterology & Hepatology
Vasilios Papastergiou, Nikos Viazis, Gerassimos J. Mantzaris
Summary: This article is linked to the papers by Jodal et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Physiology
Luuk A. van Duuren, Jonathan Ozik, Remy Spliet, Nicholson T. Collier, Iris Lansdorp-Vogelaar, Reinier G. S. Meester
Summary: This study presents a broadly applicable algorithm to efficiently optimize personalized screening policies for colorectal cancer (CRC) based on age and FIT-history. The algorithm combines a mathematical framework with an established microsimulation model to accurately estimate the costs and benefits of generated policies. The results demonstrate that personalized screening can increase health benefits compared to traditional screening, and the generated policies have concordant features with current screening recommendations.
FRONTIERS IN PHYSIOLOGY
(2022)
Review
Gastroenterology & Hepatology
Marina Hanna, Neelendu Dey, William M. Grady
Summary: Colorectal cancer is a common cancer globally and is a leading cause of cancer-related deaths. Current screening methods for colorectal cancer have limitations and many people are not compliant with screening recommendations. Novel screening tests based on advances in molecular biology, genetics, and epigenetics, as well as sequencing technologies and computational analytic methods, have been developed to improve early detection of colorectal cancer.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Medicine, General & Internal
Diana G. Redwood, Tuan A. Dinh, John B. Kisiel, Bijan J. Borah, James P. Moriarty, Ellen M. Provost, Frank D. Sacco, James J. Tiesinga, David A. Ahlquist
Summary: The study aimed to evaluate the cost-effectiveness of multitarget stool DNA testing (MT-sDNA) compared with colonoscopy and fecal immunochemical testing (FIT) for Alaska Native adults. Results showed that MT-sDNA demonstrated significant cost-effectiveness in different adherence scenarios, with clear advantages in terms of QALYs savings.
MAYO CLINIC PROCEEDINGS
(2021)
Article
Oncology
Coral Arnau-Collell, Anna Diez-Villanueva, Beatriz Bellosillo, Josep M. Auge, Jenifer Munoz, Elisabe Guino, Leticia Moreira, Anna Serradesanferm, Isabel Tora-Rocamora, Laia Bonjoch, Gemma Ibanez-Sanz, Mireia Obon-Santacana, Ferran Moratalla-Navarro, Rebeca Sanz-Pamplona, Carmen Marquez Marquez, Rebeca Rueda Miret, Rocio Perez Berbegal, Gabriel Piquer Velasco, Cristina Hernandez Rodriguez, Antoni CRIPREV Consortium, Jaume Grau, Antoni Castells, Josep M. Borras, Xavier Bessa, Victor Moreno, Sergi Castellvi-Bel
Summary: This study is the first investigation analyzing polygenic risk score (PRS) in a two-step colorectal cancer screening program. The results showed that PRS could improve the accuracy of current colorectal cancer screening, especially for higher at-risk subgroups. However, the capacity of PRS is limited and should be complemented by additional biomarkers.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Gastroenterology & Hepatology
Junfeng Xu, Long Rong, Fang Gu, Peng You, Hui Ding, Huihong Zhai, Bangmao Wang, Yanqing Li, Xianzong Ma, Fumei Yin, Lang Yang, Yuqi He, Jianqiu Sheng, Peng Jin
Summary: This study evaluated the performance of the Asia-Pacific Colorectal Screening (APCS) scoring system combined with stool DNA test in colorectal cancer screening. The results showed that this combination significantly improved the detection of early colorectal neoplasms and reduced the workload of colonoscopy.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Rune Wilkens, Michael Dolinger, Johan Burisch, Christian Maaser
Summary: Breaking through the efficacy plateau for biologic therapy in inflammatory bowel disease requires the development of personalized biomarkers and close monitoring to assess and adjust treatment outcomes in real time. Intestinal ultrasound, combined with other biomarkers, can optimize personalized treatment and improve outcomes.
Article
Oncology
Tim L. Kortlever, Manon van der Vlugt, Floor A. M. Duijkers, Ad Masclee, Roderik Kraaijenhagen, Manon C. W. Spaander, Iris Lansdorp-Vogelaar, Patrick M. Bossuyt, Evelien Dekker
Summary: Combining FIT with risk factors for CRC did not increase the yield of AN compared to FIT-only in an existing CRC screening programme.
BRITISH JOURNAL OF CANCER
(2023)
Article
Gastroenterology & Hepatology
Yazmin San Miguel, Joshua Demb, Maria Elena Martinez, Samir Gupta, Folasade P. May
Summary: The study found that delayed colonoscopy completion after an abnormal stool-based colorectal cancer screening test is associated with higher risk of CRC incidence, death, and late-stage CRC. Therefore, interventions to improve CRC outcomes should emphasize diagnostic follow-up within 1 year of abnormal screening results.
Article
Oncology
Anna Krigel, David W. Wan
Summary: Stool-based tests for colorectal cancer are recommended as first-line screening options, but have high false-positive rates. A positive stool-based test result may indicate the presence of a precancerous lesion. Positive mt-sDNA is associated with a higher risk for finding tumors on colonoscopy, especially clinically relevant serrated polyps, compared with positive FIT.
CANCER PREVENTION RESEARCH
(2022)